Cholinergic Nucleus Degeneration and Its Association with Gait Impairment in Parkinson's Disease

Overview

Journal J Neuroeng Rehabil

Publisher Biomed Central

Specialties Biomedical Engineering
Neurology
Rehabilitation Medicine

Date 2024 Jul 18

PMID 39026279

Authors

Xiaodan Zhang

Mateng Wang

Shi Yeow Lee

Yumei Yue

Zhaoying Chen

Yilin Zhang

Lulu Wang

Qiongfeng Guan

Weinv Fan

Ting Shen

Affiliations

Soon will be listed here.

Abstract

Background: The contribution of cholinergic degeneration to gait disturbance in Parkinson's disease (PD) is increasingly recognized, yet its relationship with dopaminergic-resistant gait parameters has been poorly investigated. We investigated the association between comprehensive gait parameters and cholinergic nucleus degeneration in PD.

Methods: This cross-sectional study enrolled 84 PD patients and 69 controls. All subjects underwent brain structural magnetic resonance imaging to assess the gray matter density (GMD) and volume (GMV) of the cholinergic nuclei (Ch123/Ch4). Gait parameters under single-task (ST) and dual-task (DT) walking tests were acquired using sensor wearables in PD group. We compared cholinergic nucleus morphology and gait performance between groups and examined their association.

Results: PD patients exhibited significantly decreased GMD and GMV of the left Ch4 compared to controls after reaching HY stage > 2. Significant correlations were observed between multiple gait parameters and bilateral Ch123/Ch4. After multiple testing correction, the Ch123/Ch4 degeneration was significantly associated with shorter stride length, lower gait velocity, longer stance phase, smaller ankle toe-off and heel-strike angles under both ST and DT condition. For PD patients with HY stage 1-2, there were no significant degeneration of Ch123/4, and only right side Ch123/Ch4 were corrected with the gait parameters. However, as the disease progressed to HY stage > 2, bilateral Ch123/Ch4 nuclei showed correlations with gait performance, with more extensive significant correlations were observed in the right side.

Conclusions: Our study demonstrated the progressive association between cholinergic nuclei degeneration and gait impairment across different stages of PD, and highlighting the potential lateralization of the cholinergic nuclei's impact on gait impairment. These findings offer insights for the design and implementation of future clinical trials investigating cholinergic treatments as a promising approach to address gait impairments in PD.

References

Cesar K, Yassuda M, Porto F, Brucki S, Nitrini R . MoCA Test: normative and diagnostic accuracy data for seniors with heterogeneous educational levels in Brazil. Arq Neuropsiquiatr. 2019; 77(11):775-781. DOI: 10.1590/0004-282X20190130. View

Blair J, Barrett M, Patrie J, Flanigan J, Sperling S, Elias W . Brain MRI Reveals Ascending Atrophy in Parkinson's Disease Across Severity. Front Neurol. 2020; 10:1329. PMC: 6930693. DOI: 10.3389/fneur.2019.01329. View

Barrett M, Murphy J, Zhang J, Blair J, Flanigan J, Nawaz H . Olfaction, cholinergic basal forebrain degeneration, and cognition in early Parkinson disease. Parkinsonism Relat Disord. 2021; 90:27-32. DOI: 10.1016/j.parkreldis.2021.07.024. View

Perez-Lloret S, Peralta M, Barrantes F . Pharmacotherapies for Parkinson's disease symptoms related to cholinergic degeneration. Expert Opin Pharmacother. 2016; 17(18):2405-2415. DOI: 10.1080/14656566.2016.1254189. View

Malek-Ahmadi M, Powell J, Belden C, OConnor K, Evans L, Coon D . Age- and education-adjusted normative data for the Montreal Cognitive Assessment (MoCA) in older adults age 70-99. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2015; 22(6):755-61. DOI: 10.1080/13825585.2015.1041449. View

Longhurst J, Wise M, Krist D, Moreland C, Basterrechea J, Landers M . Brain volumes and dual-task performance correlates among individuals with cognitive impairment: a retrospective analysis. J Neural Transm (Vienna). 2020; 127(7):1057-1071. PMC: 7293667. DOI: 10.1007/s00702-020-02199-7. View

Barrett M, Sperling S, Blair J, Freeman C, Flanigan J, Smolkin M . Lower volume, more impairment: reduced cholinergic basal forebrain grey matter density is associated with impaired cognition in Parkinson disease. J Neurol Neurosurg Psychiatry. 2019; 90(11):1251-1256. DOI: 10.1136/jnnp-2019-320450. View

Pasquini J, Brooks D, Pavese N . The Cholinergic Brain in Parkinson's Disease. Mov Disord Clin Pract. 2021; 8(7):1012-1026. PMC: 8485627. DOI: 10.1002/mdc3.13319. View

Ding Q, Ou Z, Yao S, Wu C, Chen J, Shen J . Cortical activation and brain network efficiency during dual tasks: An fNIRS study. Neuroimage. 2024; 289:120545. DOI: 10.1016/j.neuroimage.2024.120545. View

10.

Subotic A, Gee M, Nelles K, Ba F, Dadar M, Duchesne S . Gray matter loss relates to dual task gait in Lewy body disorders and aging. J Neurol. 2023; 271(2):962-975. DOI: 10.1007/s00415-023-12052-y. View

11.

Peterson D, Pickett K, Duncan R, Perlmutter J, Earhart G . Gait-related brain activity in people with Parkinson disease with freezing of gait. PLoS One. 2014; 9(3):e90634. PMC: 3940915. DOI: 10.1371/journal.pone.0090634. View

12.

Curtze C, Nutt J, Carlson-Kuhta P, Mancini M, Horak F . Levodopa Is a Double-Edged Sword for Balance and Gait in People With Parkinson's Disease. Mov Disord. 2015; 30(10):1361-70. PMC: 4755510. DOI: 10.1002/mds.26269. View

13.

Giladi N, McDermott M, Fahn S, Przedborski S, Jankovic J, Stern M . Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology. 2001; 56(12):1712-21. DOI: 10.1212/wnl.56.12.1712. View

14.

Rochester L, Galna B, Lord S, Burn D . The nature of dual-task interference during gait in incident Parkinson's disease. Neuroscience. 2014; 265:83-94. DOI: 10.1016/j.neuroscience.2014.01.041. View

15.

Ali N, Tian H, Thabane L, Ma J, Wu H, Zhong Q . The Effects of Dual-Task Training on Cognitive and Physical Functions in Older Adults with Cognitive Impairment; A Systematic Review and Meta-Analysis. J Prev Alzheimers Dis. 2022; 9(2):359-370. DOI: 10.14283/jpad.2022.16. View

16.

Morris R, Martini D, Madhyastha T, Kelly V, Grabowski T, Nutt J . Overview of the cholinergic contribution to gait, balance and falls in Parkinson's disease. Parkinsonism Relat Disord. 2019; 63:20-30. PMC: 6682416. DOI: 10.1016/j.parkreldis.2019.02.017. View

17.

Bohnen N, Yarnall A, Weil R, Moro E, Moehle M, Borghammer P . Cholinergic system changes in Parkinson's disease: emerging therapeutic approaches. Lancet Neurol. 2022; 21(4):381-392. PMC: 8985079. DOI: 10.1016/S1474-4422(21)00377-X. View

18.

Jia X, Wang J, Sun H, Zhang H, Liao W, Wang Z . RESTplus: an improved toolkit for resting-state functional magnetic resonance imaging data processing. Sci Bull (Beijing). 2023; 64(14):953-954. DOI: 10.1016/j.scib.2019.05.008. View

19.

Kelly V, Eusterbrock A, Shumway-Cook A . A review of dual-task walking deficits in people with Parkinson's disease: motor and cognitive contributions, mechanisms, and clinical implications. Parkinsons Dis. 2011; 2012:918719. PMC: 3205740. DOI: 10.1155/2012/918719. View

20.

Bohnen N, Kanel P, Zhou Z, Koeppe R, Frey K, Dauer W . Cholinergic system changes of falls and freezing of gait in Parkinson's disease. Ann Neurol. 2019; 85(4):538-549. PMC: 6450746. DOI: 10.1002/ana.25430. View